A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Bevacizumab-Naïve Subjects With Progressive High Grade Glioma Following Prior Therapy and Subjects With Newly Diagnosed Glioblastoma

Trial Profile

A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Bevacizumab-Naïve Subjects With Progressive High Grade Glioma Following Prior Therapy and Subjects With Newly Diagnosed Glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Sirolimus (Primary) ; Bevacizumab; Lomustine; Marizomib; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors AADi
  • Most Recent Events

    • 15 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top